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ABSTRACT 
Whereas atherogenicity of dietary lipids has been largely studied, relatively little is 
known about the possible contribution of dietary amino acids to macrophage foam-cell 
formation, a hallmark of early atherogenesis. Recently, we showed that leucine has anti-
atherogenic properties in the macrophage model system. In the current study, an in-
depth investigation of the role of leucine in macrophage lipid metabolism was conducted 
by supplementing humans, mice, or cultured macrophages with leucine. Macrophage 
incubation with serum obtained from healthy adults supplemented with leucine (5 g/d, 3 
weeks) significantly decreased cellular cholesterol mass by inhibiting the rate of 
cholesterol biosynthesis and increasing cholesterol efflux from macrophages. Similarly, 
leucine supplementation to C57BL/6 mice (8 weeks) resulted in decreased cholesterol 
content in their harvested peritoneal macrophages (MPM) in relation with reduced 
cholesterol biosynthesis rate. Studies in J774A.1 murine macrophages revealed that 
leucine dose-dependently decreased cellular cholesterol and triglyceride mass. 
Macrophages treated with leucine (0.2 mM) showed attenuated uptake of very low-
density lipoproteins (VLDL) and triglyceride biosynthesis rate, with a concurrent down-
regulation of diacylglycerol acyltransferase-1 (DGAT1), a key enzyme catalyzing 
triglyceride biosynthesis in macrophages. Similar effects were observed when 
macrophages were treated with α-ketoisocaproate (KIC), a key leucine metabolite. 
Finally, both in vivo and in vitro leucine supplementation significantly improved 
macrophage mitochondrial respiration and ATP production. The above studies, 
conducted in human, mice, and cultured macrophages, highlight a protective role for 
leucine attenuating macrophage foam-cell formation by mechanisms related to the 
metabolism of cholesterol, triglycerides, and energy production.      
Keywords: Leucine, α-ketoisocaproate, macrophages, lipid metabolism, foam-cell 
formation 
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Abbreviations: MPM, mouse peritoneal macrophages; VLDL, very low-density 
lipoproteins; DGAT1, diacylglycerol acyltransferase-1; KIC, α-ketoisocaproate; CVD, 
cardiovascular diseases; BCAA, branched-chain amino acids; HFD, high-fat diet; MI, 
myocardial infarction; apoE-/-, apolipoprotein E deficient; LDLR-/-, low-density lipoprotein 
receptor deficient; I/R, ischemia/reperfusion; HMB, β-hydroxy-β-methylbutyrate; IVA, 
isovaleric acid; DMEM, Dulbecco's modified Eagle’s medium; PBS, phosphate buffered 
saline; DCFH-DA, 2′,7′-dichlorofluorescin-diacetate; FITC, fluorescein-isothiocyanate; 
DMSO, dimethyl sulfoxide; DMF, dimethylformamide; FBS, fetal bovine serum; BSA, 
bovine serum albumin; LDH, lactate dehydrogenase; FCCP, carbonyl cyanide-4 
(trifluoromethoxy) phenylhydrazone; WHR, waist-to-hip ratio; ATCC, American Type 
Culture Collection; ROS, reactive oxygen species; AggLDL, aggregated LDL; LSC, liquid 
scintillation counting; TLC, thin-layer chromatography; OCR, oxygen consumption rate; 
HDL, high-density lipoproteins; BCAT, branched-chain aminotransferase; BCKDH, 
branched-chain α-keto acid dehydrogenase. 
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1. INTRODUCTION 
Atherosclerosis, a progressive disease characterized by the accumulation of lipids and 
fibrous elements in the large arteries (1), is the pathogenic mediator of most 
cardiovascular diseases (CVD), a leading cause of morbidity and mortality worldwide (2). 
A crucial early step in atherosclerosis development is the infiltration of monocytes from 
the circulation into the arterial wall (3), where they differentiate into macrophages. Intimal 
macrophages take up native and modified lipoproteins, accumulate lipids, and are 
transformed into foam-cells, a hallmark feature of early atherogenesis (1, 4). Although a 
considerable body of evidence supports the link between dietary fat and atherogenesis, 
relatively little is known about the contribution of other key dietary components, such as 
amino acids, to the process of macrophage foam-cell formation and the onset of 
atherosclerosis (5). Controversial findings have been reported regarding the relationship 
between specific amino acids, atherosclerosis, and CVD risk. For instance, excess 
dietary methionine (6), and its metabolite, homocysteine (7-9), as well as glutamate and 
glutamine (10, 11), have been associated with increased risk of  atherosclerosis, CVD 
and related cardio-metabolic disorders. 
Branched-chain amino acids (BCAA), leucine, isoleucine, and valine, are 
essential amino acids that share a distinct catabolic pathway (12). High circulating BCAA 
were found in subjects with dyslipidemia, obesity, and cardio-metabolic diseases (10, 
13-17). Despite these associations, BCAA intakes were shown to be cardio-protective by 
improving parameters of inflammation, blood pressure, and insulin resistance, 
independent of metabolic conditions (18), and were associated with lower prevalence of 
obesity and decreased risk of diabetes development in men and women (19-21). 
Moreover, dietary BCAA were shown to possess cardio-protective effects in a heart-
failure rat model (22), and to improve hepatic steatosis by modulating lipid synthetic 
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pathways in obese mice (23). Particularly, increasing evidence indicate that leucine has 
unique properties in metabolic regulation, beyond its known role in de novo protein 
synthesis (24, 25). The beneficial effects of leucine in lipid and glucose metabolism have 
been studied in animals and in humans (26). Dietary leucine attenuated obesity, 
hyperglycemia, and hypercholesterolemia (27), and ameliorated adipose tissue 
inflammation, hepatic lipid deposition, and insulin resistance in high-fat diet (HFD) fed 
mice (28). Recently, leucine intake was associated with improved measures of arterial 
stiffness and atherosclerosis in women (29). In C57BL/6 mice subjected to experimental 
myocardial infarction (MI), a high-leucine diet attenuated fibrosis and apoptosis, and 
improved cardiac structure, function, and post-MI survival (30). Moreover, leucine 
supplementation improved plasma lipid profile in apoE-/- mice protecting from 
atherosclerotic progression (31), and enhanced the hypolipidemic and athero-protective 
effects of nicotinic acid administration in low-density lipoprotein receptor deficient (LDLR-
/-) mice (32). 
Due to its unique role in metabolism, there is a growing interest to study the 
metabolic effects of leucine catabolism-derived metabolites (Figure 1). For instance, the 
cardio-protective role of KIC, the first metabolite from leucine catabolism, was recently 
demonstrated by attenuated ischemia-reperfusion (I/R) injury in isolated mouse hearts 
(33). However, little is known about the effects of leucine and its metabolites in 
macrophage-foam cell formation or atherogenesis. Recently, we have screened for anti- 
or pro-atherogenic amino acids using a macrophage model system, and identified 
leucine as a potent amino acid which dose-dependently decreased macrophage 
cholesterol and triglyceride content in vitro (34). Nevertheless, whether leucine is able to 
inhibit macrophage foam-cell formation in vivo, and its lipid-lowering mechanisms, 
remain unclear. The current investigation aims to elucidate the role of leucine in 
macrophage lipid metabolism and the concomitant foam-cell formation process by 
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supplementing humans, mice, and cultured macrophages with leucine. Moreover, the 
effects of key leucine catabolites (KIC, β-hydroxy-β-methylbutyrate, HMB, or isovaleric 
acid, IVA) on lipid metabolism were assessed in the macrophage model system. 
 
 
2. EXPERIMENTAL PROCEDURES 
2.1. Materials 
L-leucine (L8912), IVA (129542), Dulbecco's modified Eagle’s medium (DMEM, D5796), 
phosphate buffered saline (PBS, D8537), triglyceride determination kit (containing the 
T2449 triglyceride reagent and the F6428 free glycerol reagent), 2′,7′-dichlorofluorescin-
diacetate (DCFH-DA, D6883), fluorescein-isothiocyanate (FITC, F7250), dimethyl 
sulfoxide (DMSO, D8418), dimethylformamide (DMF, 227056), glucose solution (G8769, 
2.5 mM), and phosphatase inhibitor cocktail (P5726), were purchased from Sigma-
Aldrich (St. Louis, MO, USA). KIC (Alfa Aesar H60076) and HMB (Alfa Aesar 42722) 
were purchased from Tzamal D-Chem Laboratories Ltd. Cholesterol measurement kit 
(11491458) and protease inhibitor cocktail tablets (cOmplete 11231400) were obtained 
from Roche Diagnostics (Mannheim, Germany). Leucine-deficient DMEM, heat 
inactivated fetal bovine serum (FBS), bovine serum albumin solution (BSA, 10%), 
sodium pyruvate solution (100mM), L-glutamine solution (200 mM), and penicillin-
streptomycin-nystatin solution, were purchased from Biological Industries (Beit Haemek, 
Israel). [9,10-3H(N)]-oleic acid (NET289001MC), [3H]-acetic acid sodium salt 
(NET003005MC), and [1,2-3H(N)]-cholesterol (NET139001MC), were purchased from 
Perkin Elmer (Waltham, MA, USA). Lactate dehydrogenase (LDH) determination kit and 
silica gel plates (60F254) were purchased from Merck (Darmstadt, Germany). Exclusion 
chromatography PD-10 columns (17-0851-01) were obtained from GE healthcare 
(Buckinghamshire, UK). Bradford reagent was purchased from Bio-Rad (Hercules, CA, 
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USA). RNA purification kit (MasterPure TM) was obtained from Epicentre 
Biotechnologies (Madison, WI, USA). cDNA preparation kit and Absolute Blue qPCR 
ROX mix were purchased from Thermo Scientific (Epsom, UK). Seahorse XF medium 
(102353-100), and Seahorse XF Cell Mito Stress Test Kit (103015-100) including 
oligomycin, carbonyl cyanide-4 (trifluoromethoxy) phenylhydrazone (FCCP), and a mix 
of rotenone/antimycin A, were from Seahorse Bioscience (Agilent Technologies 
distributor, Petach Tikva, Israel). L-leucine approved for human consumption was 
obtained from Fagron Inc (St. Paul, MN, USA). 
 
2.2. Clinical trial 
A randomized interventional study was conducted in accordance with the principles of 
the Declaration of Helsinki (ID: 0566-16-RMB CTIL), and registered in the US National 
Library of Medicine (http://www.clinicaltrials.gov ID: NCT03180775).  
2.2.1. Study population 
Subjects were recruited at the Rambam Health Care Campus, Haifa, Israel. Volunteers 
were screened for eligibility after signing an informed consent document for all the study-
related procedures. The inclusion criteria were healthy male subjects, in the age range 
between 18-50 years old. The exclusion criteria were any renal, pulmonary, or 
endocrinal condition, diabetes, cancer, or morbid obesity (BMI >40 kg/m2), smokers, or 
consumption of more than two alcoholic drinks per day. Subjects who were using any 
kind of amino acid supplements were also excluded from the study. 
2.2.2. Leucine administration 
Each volunteer was asked to fast overnight before the beginning of the study. The day of 
the first visit (baseline, 0 h), subjects were provided with a solution of leucine (5 g 
dissolved in 250 mL of fresh water) which was consumed in a single dose. Afterwards, 
daily administration of leucine was carried out for 3 weeks. Leucine was provided in 
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packages containing 5 g of the soluble powder, which the participants dissolved in fresh 
water and consumed each morning throughout the study. Leucine dose (5 g/d) was set 
up based on the average leucine daily intake reported in adults (5.3±0.1 g/d) (35). 
2.2.3. Anthropometric and laboratory measures 
During the period between blood collections, the participants were allowed to continue 
with their usual activities and dietary habits, and were advised to avoid any other dietary 
supplements. Fasting blood samples were drawn from the patients on the first visit at 
baseline, after 1 h of the first leucine dose (1 h), and at end of the study (21 d). From 
each participant, serum was obtained by centrifugation (1000 g, 10 min) and stocked at -
20 °C for further analyses. Biochemical parameters of the serum including the levels of 
leucine, glucose, lipid profile, liver enzyme, and renal function, were assessed at the 
Laboratory of Clinical Biochemistry of the Rambam Health Care Campus, Haifa, Israel, 
at baseline and at the end of the dietary intervention (21 d). Each participant was 
subjected to the following anthropometric measurements: body weight, height, waist and 
hip circumferences. Next, body composition was assessed using a segmental body 
composition monitor (Tanita®, Tokyo, Japan) (36), and the waist-to-hip ratio (WHR) was 
calculated by dividing waist circumference by hip circumference measures.  
2.2.4. Ex vivo studies in human serum-supplemented J774A.1 macrophages 
J774A.1 murine macrophage-like cell line was obtained from the American Type Culture 
Collection (ATCC, Rockville, MD, USA) and maintained in a humidified incubator (37 °C, 
5% CO2) in DMEM (1% penicillin-streptomycin-nystatin solution, 1% L-glutamine, 1% 
sodium pyruvate) supplemented with 5% heat-inactivated FBS. For the ex vivo 
experiments, cultured J774A.1 macrophages were incubated overnight in serum-free 
DMEM (1% penicillin/streptomycin/nystatin solution, 1% L-glutamine, 1% sodium 
pyruvate), supplemented with 0.2% BSA and 2.5% serum obtained from the leucine-
supplemented participants at baseline, 1 h, or at 21 d. Serum concentration was chosen 
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based on previous studies evaluating the effects of human serum addition on lipid 
metabolism in different cell types, such as MPM and Fu5AH hepatoma cells (37, 38). 
The human serum-mediated effects on macrophage lipids content and lipids metabolism 
were assessed as described in the following sections (2.5. Macrophage lipid contents 
and metabolism). 
 
2.3. Mice study 
Animal experiments were carried out in accordance with the Guide for the Care and Use 
of Laboratory Animals of the NIH, USA. The protocol for the study was approved by the 
Committee for Supervision of Animal Experiments of the Technion – Israel Institute of 
Technology (Approval number: IL045-04-16). Male C57BL/6, 8-weeks old mice 
(provided by Envigo, Jerusalem, Israel) were bred and housed in pathogen-free 
conditions at the Animal Care Facility of the Rappaport Faculty of Medicine, Technion. 
2.3.1. Leucine administration to mice 
Mice were randomly divided in 2 experimental groups (n=8): 1) Control group, which 
received standard chow and water with no supplementation, and 2) Leucine 
supplemented group, which received standard chow and leucine (1%, w/v) via their 
drinking water for 8 weeks. Leucine dose was set to double its amount provided by daily 
chow (average consumption). This dose was based on previous reports demonstrating 
the metabolic benefits of leucine without affecting food intake or weight gain in mice (30). 
Data on the macronutrient and the amino acid composition of the standard chow as 
provided by the manufacturer are detailed in the supporting information (Table S1). The 
food intake and body weight of the mice were monitored every two and seven days, 
respectively, during the course of the 8-week study. 
2.3.2. Serum analyses 
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Blood was collected from the retro-orbital plexus of the mice under isoflurane anesthesia 
(via inhalation) after overnight fasting. The serum was separated from the clotted blood 
by centrifugation (1000 g, 10 min). Serum cholesterol and triglycerides were measured 
using the commercially available kits detailed in the Materials section. Serum leucine 
levels, determined by HPLC (34), were assessed at the Laboratory of Clinical 
Biochemistry of the Rambam Health Care Campus, Haifa, Israel.  
2.3.3. Aortic and liver lipid analyses  
Aortas and livers were rapidly removed from the euthanized mice and kept at -80°C. 
Aortas (including the ascending aorta, the aortic arch, and the descending thoracic 
aorta) were cleared of adhering fat and connective tissue before further analyses. Aorta 
or liver samples were homogenized in PBS (containing protease inhibitor and 
phosphatase inhibitor cocktails) using a Polytron Homogenizer (Kinematica AG, Littau, 
Switzerl nd) at 60W for 1 min. Aorta or liver homogenates were then centrifuged (5000 
g, 20 min) and the supernatants were analyzed for protein levels by the Lowry assay 
(39). To assess the aortic or liver lipid composition, lipids were extracted from the 
homogenates with hexane:isopropanol (3:2, v:v), and the hexane phase was evaporated 
under nitrogen. The amounts of aortic or liver cholesterol or triglycerides were 
determined spectrophotometrically using the commercially available kits described in the 
Materials section. Data were normalized to protein levels. 
2.3.4. Mouse peritoneal macrophages (MPM) isolation and culture 
Three days after intraperitoneal injection of 3 mL of thioglycollate (40 g/L) into each 
mouse, MPM were harvested from the peritoneal fluids of the euthanized mice. MPM 
were then plated and incubated in a humidified incubator (37°C, 5% CO2) in DMEM (1% 
penicillin-streptomycin-nystatin solution, 1% L-glutamine, 1% sodium pyruvate) 
supplemented with 5% heat-inactivated FBS, for further lipid content and metabolism 
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studies, as described in the following sections (2.5. Macrophage lipid contents and 
metabolism). 
 
2.4. J774A.1 macrophage study 
For experiments with leucine or its metabolites, cultured J774A.1 macrophages (ATCC, 
Rockville, MD, USA) were incubated overnight (20 h) in leucine-deficient DMEM (1% 
penicillin-streptomycin-nystatin solution, 1% L-glutamine, 1% sodium pyruvate) 
supplemented with 5% heat-inactivated FBS and increasing concentrations (0.02, 0.05, 
0.1, 0.2, 1 and 2 mM) of leucine, KIC, HMB, or IVA. The range of concentrations was 
determined based on the physiological or supra-physiological plasma levels of leucine or 
its metabolites, KIC or HMB (IVA plasma levels in adults are not described), and on 
previous reports (14, 34, 40-43).  
2.4.1. J774A.1 macrophage toxicity and proliferation 
The effect of increasing levels of leucine or its metabolites on the toxicity of J774A.1 
macrophages were assessed by measuring the release of LDH from the cells into the 
culture medium (34, 44). The remaining cells in the plates were dissolved in 0.1 M 
NaOH, for cellular protein quantification by the Lowry assay (39). Results were 
expressed as LDH units/mg cell protein. J774A.1 macrophages counting was performed 
after cell treatment with leucine (0.2 mM), in an automated cell counter (Countess II, 
Thermo Fisher, Israel). 
2.4.2. J774A.1 macrophage oxidative stress – DCFH-DA assay  
Intracellular generation of reactive oxygen species (ROS) in macrophages was 
evaluated in J774A.1 macrophages by the DCFH-DA probe as previously described 
(45). Cells were incubated with DCFH-DA (10 µM, in PBS) in the dark for 40 min at 
37°C. Next, the cells were washed with PBS (2x), and the adherent cells were detached 
by gentle scraping, resuspended in PBS, and transferred to special tubes. Measurement 
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of cellular fluorescence was made by flow cytometry and performed using a BD 
LSRFortessa (BD Biosciences, San Jose, CA, USA).  
 
2.5. Macrophage lipid contents and metabolism 
2.5.1. Cellular cholesterol or triglyceride quantification 
Cellular lipids were extracted twice with a mixture of hexane:isopropanol (3:2, v:v), and 
the hexane phase was evaporated under nitrogen. Cellular cholesterol or triglyceride 
contents were determined spectrophotometrically using the commercially available kits 
described in the Materials section. The remaining cells in the plates were dissolved in 
0.1 M NaOH for cellular protein determination by the Lowry assay (39). Cholesterol or 
triglycerides mass values were normalized to cellular protein levels. In some 
experiments, J774A.1 macrophages were loaded overnight (20 h) with isolated VLDL 
(triglycerides-rich lipoprotein, 50 µg/mL) or with aggregated LDL (AggLDL, cholesterol-
rich lipoproteins, 50 µg/mL). AggLDL were prepared by vortexing the isolated LDL during 
90 s, resulting in a turbid solution. Then, cells were washed with PBS (1x) and incubated 
for 20 h with leucine (0.2 mM) in leucine-deficient DMEM. Next, macrophage lipids were 
extracted, and cellular cholesterol or triglycerides contents were determined as 
described above. 
2.5.2. Human serum-mediated cholesterol efflux 
J774A.1 macrophages were pre-incubated with [3H]-labeled cholesterol (2.5 µCi/ml) for 1 
h at 37°C, followed by cell wash with PBS (x2) and further incubation for 3 h at 37°C, in 
the absence or presence of 2.5% serum obtained from the participants of the clinical 
trial, at baseline, 1 h, or at 21 d. At the end of the incubation period, the efflux media 
were collected and the [3H]-labels in 500 µL of each sample were determined by liquid 
scintillation counting (LSC) (β-counter, Packard Tri Carb 2100TR, PerkinElmer, 
Waltham, MA, USA). The remaining cells in each well were washed with PBS (x2), 
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solubilized overnight in 0.1 M NaOH, and the amount of [3H]-labels in 500 µL of each 
lysate was determined LSC. Total cellular [3H]-cholesterol was calculated as the sum of 
the radioactivity in the efflux medium plus the radioactivity in the lysates. Human serum-
mediated cholesterol efflux corresponded to the % of total [3H]-cholesterol released into 
the medium (46). Results were expressed as % serum-mediated cholesterol efflux vs 
baseline. 
2.5.3. Cholesterol biosynthesis rate 
Macrophage cholesterol biosynthesis rate was assessed after a 4 h-incubation period at 
37°C with [3H]-acetic acid (3.3 µCi/mL) in serum-free DMEM supplemented with 0.2% 
BSA (47). At the end of the incubation time, cells were washed with PBS (x2), and lipids 
were extracted with hexane:isopropanol (3:2, v:v). After hexane evaporation, lipids were 
dissolved in CHCl3 and separated by thin-layer chromatography (TLC) on silica gel 
plates, nd developed in hexane:ether:acetic acid (130:30:1.5, v:v:v). Unesterified 
cholesterol spots were visualized by iodine vapor using an appropriate standard for 
identification, and [3H]-labels were counted by LSC. The remaining cells in the plate 
were dissolved overnight in 0.1 M NaOH for cellular protein determination by the Lowry 
assay (39). [3H]-labels counts were normalized to cellular protein levels, and expressed 
as cpm/mg cell protein. 
2.5.4. Triglycerides biosynthesis rate 
Macrophages were washed with PBS (1x) and the rate of triglycerides biosynthesis was 
assessed after a 4 h-incubation period at 37°C with [3H]-oleic acid (3.3 µCi/mL) in 
serum-free DMEM supplemented with 0.2% BSA (34, 47, 48). At the end of the 
incubation time, cells were washed with PBS (x2), and lipids were extracted. After 
evaporation of the hexane phase, lipids were dissolved in CHCl3 and separated by TLC 
on silica gel plates, and developed in hexane:ether:acetic acid (130:30:1.5, v:v:v). 
Triglycerides spots were visualized by iodine vapor using an appropriate standard for 
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identification, and [3H]-labels were counted by LSC. The remaining cells in the plate 
were dissolved overnight in 0.1 M NaOH for cellular protein quantification by the Lowry 
assay (39). [3H]-labels counts were normalized to cellular protein levels, and expressed 
as cpm/mg cell protein. 
2.5.5. Triglyceride degradation rate 
Following the triglyceride biosynthesis rate procedure, cells were washed with PBS (x2) 
and incubated for additional 4 h in serum-free DMEM supplemented with 0.2% BSA. At 
the end of the second incubation period, cells were washed with PBS (x2) and lipids 
were extracted. [3H]-labels were analyzed as described above. The remaining cells in 
the plate were dissolved in 0.1 M NaOH for cellular protein determination by the Lowry 
assay (39). [3H]-labels counts were normalized to cellular protein levels, and expressed 
as cpm/mg cell protein.  
2.5.6. Isolation of lipoproteins 
VLDL and LDL were isolated from plasma of healthy humans by discontinuous density 
gradient ultracentrifugation as previously described (47, 49). VLDL fraction was 
separated at d= 1.006 g/mL, and LDL fraction at d= 1.063. Protein concentration was 
determined by the Bradford protein assay. 
2.5.7. Lipoprotein labeling and VLDL uptake analysis 
Isolated VLDL (0.8 mg/mL) were labelled with FITC (0.2 mg/mL DMF) as previously 
described (34, 50). Macrophages were incubated for 4 h at 37°C with FITC-conjugated 
VLDL (24 µg/mL) in serum-free DMEM supplemented with 0.2% BSA. Next, cells were 
washed (x2) and resuspended in PBS to be transferred to special tubes. The uptake of 
FITC-conjugated VLDL by the macrophages was determined by flow cytometry (BD 
LSRFortessa, BD Biosciences, San Jose, CA, USA) (34, 51).  
 
2.6. Assessment of mitochondrial function in macrophages 
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Cellular oxygen consumption rate (OCR) was measured in J774A.1 macrophages and in 
MPM using a Seahorse Bioscience XF96 analyzer (Seahorse Bioscience, Billerica, MA) 
following the recommended procedure and conditions of the manufacturer. The key 
parameters of mitochondrial function, baseline macrophage respiration, mitochondrial 
ATP production, and maximal mitochondrial respiration, were estimated after oxygen 
consumption rate (OCR) measurements. This approach requires the use of 
mitochondrial inhibitors: oligomycin (blocks ATP synthase), FCCP (uncoupling agent, 
makes the inner mitochondrial membrane permeable for protons and disrupts 
mitochondrial potential), and rotenone and antimycin A (inhibit complexes I and III, 
respectively, to shut down mitochondrial respiration) (52, 53). Macrophages were 
seeded in XF96 cell culture microplates (V3-PS Seahorse Bioscience) and incubated at 
37°C, 5% CO2 for 20 h. The day prior to the assay, a sensor cartridge was hydrated 
overnight with Seahorse XF Calibrant (200 µL/well) in a non-CO2 incubator, at 37°C. The 
day of the experiment, the assay medium was prepared by supplementing Seahorse XF 
Base Medium with 1 mM pyruvate, 2 mM glutamine, and 10 mM glucose, and the pH 
was adjusted to 7.4 with 0.1 M NaOH, followed by sterilization by filtration (0.22 µm), and 
kept at 37°C until use. The assay was initiated by carefully washing the cells (3x) with 
the assay medium, without disturbing the cell monolayer from each well, and 1 h-
incubation with 180 µL of the same assay medium at 37°C in a CO2-free incubator, to 
allow media temperature and pH to reach equilibrium before the first-rate measurement. 
For OCR measurement, stock solutions of oligomycin, FCCP, and a mix of rotenone and 
antimycin A were prepared in assay medium and loaded into the appropriate ports of the 
previously hydrated sensor cartridge as follows: Port A: Oligomycin 1 µM, 20 µL; Port B: 
FCCP 0.5 µM, 22 µL; Port C: Rotenone/antimycin A 100 µM, 25 µL. The corresponding 
calibration and equilibration times were followed by 3-4 cycles of mixing, waiting, and 
measurement (4, 0, and 3 min, respectively) after each injection. Once the program 
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finished, protein concentrations of the samples in each well were determined by the 
Lowry assay (39). Mitochondrial OCR results were used to calculate mitochondrial basal 
respiration, ATP production, and maximal mitochondrial respiration, and were reported in 
pmol/min/mg cell protein. 
 
2.7. Quantitative polymerase chain reaction (qPCR) 
Total RNA was extracted from J774A.1 macrophages with MasterPureTM RNA 
purification kit. cDNA was generated from 1 µg of total RNA with ThermoScientific cDNA 
kit. Using Absolute Blue qPCR ROX mix, products of the reverse transcription were 
subjected to qPCR using TaqMan gene expression assays with a Rotor-Gene 6000 
amplification detection system. mRNA data were normalized to GAPDH used as the 
housekeeping gene. The primers used for mouse DGAT1, CD36, and GAPDH were 
designed by Primer Design (South Hampton, UK): DGAT1 sense primer, 
TGGTGGAATGCTGAGTCTG; DGAT1 antisense primer, 
GGTCAAAAATACTCCTGTCCTG; CD36 sense primer, 
CAGCAGCAAAATCAAGGTTAAA; CD36 antisense primer, 
TCGGGGTCCTGAGTTATATTT. 
 
2.8. Statistical analysis  
Results are presented as mean±SEM of at least three independent observations. 
Statistical analyses were performed using SPSS 17.0 software (SPSS Inc. IBM, 
Chicago, IL, USA). One-way ANOVA followed by Bonferroni post-hoc tests were used to 
compare the means between more than two experimental groups (i.e. different 
compounds concentrations vs. control). The Independent-Samples T test was used to 
compare the means between two experimental groups (i.e. specific compound vs. 
control). p<0.05 was considered statistically significant.  
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3. RESULTS 
3.1. Anti-atherogenic properties of human serum harvested following leucine 
supplementation to healthy volunteers 
The effects of leucine on serum atherogenicity were studied in healthy male adults 
supplemented with leucine (5 g/d). Seven of the eight participants recruited completed 
the instructions on leucine supplementation throughout the whole period (3 weeks), and 
were included in the study. None of the participants reported any adverse effects related 
to the dietary intervention. Anthropometric and biochemical characteristics of the 
subjects at baseline and at 21 d are shown in Table 1. The enrolled subjects were men 
in the age range of 21-38 years, non-smokers. All participants were non-obese adults, 
with a mean BMI of 24.5±0.8 (range: 21.6-28.3), and no significant differences were 
observed in body weight, body fat (%) or WHR, throughout the study. Whereas serum 
glucose, lipid profile, and other biochemical parameters did not significantly change, 
leucine serum levels were significantly higher at the end of the intervention and 
increased by 36%, from 159.4±10.3 µM at baseline, up to 217.3±23.6 at 21 d (p<0.05).  
Next, serum samples that were obtained from the participants at baseline, 1 h 
and 21 d (n=7 per each time point) were used to study the effects of leucine 
supplementation on macrophage atherogenicity ex vivo. J774A.1 macrophages were 
incubated for 20 h in serum-free DMEM supplemented with 2.5% human serum 
samples. Cholesterol content was significantly reduced in cells incubated with 21 d-
serum compared to baseline serum (by 15%, p<0.05, Figure 2A). To explain the 
observed decrease in macrophage cholesterol content, the effects of the human serum 
on cholesterol metabolism in J774A.1 macrophages were studied next by determining 
the rate of cholesterol biosynthesis and cholesterol efflux. Accordingly, J774A.1 
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macrophages incubated with 21 d-serum showed a significant reduction in cholesterol 
biosynthesis rate (by 11%, p<0.05, Figure 2B) when compared with cells incubated with 
baseline-serum. Moreover, leucine supplementation for 21 d resulted in a significant 
increase of the serum ability to induce cholesterol efflux from macrophages (10%, 
p<0.01, Figure 2C).  
 
3.2. Lipid-lowering effects in MPM and liver from leucine-supplemented mice  
Similar to the human study, leucine supplementation had no significant effects on the 
mice body weight, or serum lipid profile (Table 2). However, leucine significantly 
decreased the cholesterol content in MPM by 30% (p<0.05, Figure 3A) in relation with a 
significant decrease in cholesterol biosynthesis rate compared to the control group (by 
59%, p<0.05, Figure S1A). However, no significant difference was found in the MPM 
triglyceride content between both groups (Figure 3B). The lipid-lowering effects of 
leucine supplementation were observed in other tissues as well. In livers isolated from 
leucine-supplemented mice a significant decrease in both cholesterol and triglyceride 
content was found (13%, p<0.05, and 45%, p<0.01, respectively, Figure 3C and D). 
Finally, while no significant effects were observed in the aortic cholesterol content, a 
trend toward decreased triglyceride content was found in aortas isolated from leucine-
supplemented mice, in comparison with the control group (by 51%, p=0.052, Figure 
S1B).  
 
3.3. Lipid-lowering effects of leucine in J774A.1 macrophages  
To gain more insight into the metabolic mechanisms by which leucine attenuates lipid 
accumulation in macrophages, J774A.1 murine macrophages were incubated with 
increasing concentrations of leucine with or without lipid loading (VLDL for triglyceride 
loading, and AggLDL for cholesterol loading). In accordance with the in vivo data, 
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leucine supplementation induced a dose-dependent decrease in macrophage 
cholesterol mass by up to 30% at 0.2-1.0 mM (p<0.001, Figure 4A). Accordingly, leucine 
(0.2 mM) inhibited the accumulation of cholesterol in macrophages loaded with AggLDL. 
As shown in Figure 4B, an overnight incubation with 50 µg/mL of AggLDL caused a 
significant increase in cholesterol mass in control macrophages (2.2-fold, p<0.001), 
which was significantly attenuated in the leucine-treated cells (by 34%, p<0.001). 
Leucine treatment resulted in a significant and dose-dependent decrease in 
macrophage triglyceride content, from 23% already at 0.02 mM (p<0.05), up to 56% at 
the higher concentration tested (2 mM, p<0.001, Figure 4C). In accordance, leucine-
supplementation significantly attenuated the accumulation of triglycerides in VLDL-
loaded macrophages. Whereas an overnight incubation with VLDL (50 µg/mL) caused a 
significant increase in cellular triglyceride mass (66%, p<0.001), the triglyceride content 
in VLDL-loaded macrophages was significantly decreased after leucine supplementation 
(0.2 mM) to values even lower than those observed in non-loaded cells (by 62%, 
p<0.001, vs VLDL-loaded macrophages; and by 37%, p<0.05, vs non-loaded 
macrophages, Figure 4D).  
 
3.4. The effects of leucine on triglyceride metabolism in cultured J774A.1 
macrophages  
As leucine supplementation to J774A.1 macrophages was found to have a marked effect 
of decreasing macrophage triglyceride accumulation, metabolism of triglycerides was 
assessed next in J774A.1 macrophages treated with non-toxic levels of leucine (0.2 mM, 
Figure S2). Macrophage triglyceride content is determined by a balance between the 
rate of cellular triglyceride biosynthesis, the rate of their hydrolysis, and the uptake of 
triglyceride-rich lipoproteins by macrophages (e.g. VLDL) (54, 55). The effect of leucine 
on macrophage triglyceride biosynthesis rate was determined by measuring the 
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incorporation of [3H]-oleic acid into cellular triglycerides. As shown in Figure 5A, 
J774A.1 macrophages treated with leucine showed a marked decrement in triglyceride 
biosynthesis rate by 77% (p<0.001), compared to control cells. Accordingly, DGAT1, a 
key enzyme in the triglyceride biosynthetic pathway in macrophages (56), was 
significantly down-regulated (by 30%, p<0.05, Figure 5B). Additionally, degradation of 
triglycerides in leucine-treated macrophages was studied after incubating cells loaded 
with [3H]-oleic acid in free-serum medium. Leucine addition to cultured macrophages 
resulted in a non-significant increase of the triglyceride degradation rate compared to 
control cells (43% vs 38%, p>0.05, respectively). Using FITC-labeled VLDL, leucine 
treatment was found to decrease the macrophage uptake of VLDL by 20% (p<0.01, 
Figure 5C) with a non-significant trend towards decreased mRNA levels of its 
transporter, CD36 (Figure 5D).  
 
3.5. KIC, the first leucine metabolite, decreases macrophage lipid content  
According to the catabolic pathway that characterizes BCAA, leucine is first converted to 
KIC (Figure 1), which is subsequently decarboxylated and converted to the 
corresponding acyl-CoA derivative (12), or alternatively, oxidized to HMB (57). To 
determine if the observed protective effects of leucine against lipid accumulation can 
also be exerted by its metabolites, J774A.1 macrophages were supplemented with 
increasing concentrations of KIC, HMB, or IVA (0-2 mM), and their effects on lipid 
contents were assessed. At the examined concentrations, these compounds showed no 
cytotoxic effects on J774A.1 macrophages (Figure S3). A significant and dose-
dependent decrease in cellular triglyceride and cholesterol mass were observed after 
treating the cells with KIC. Similar to leucine supplementation, KIC treatment (0.2 mM) 
caused a significant reduction in macrophage cholesterol mass (26%, p<0.01, Figure 
6A) and triglyceride mass (50%, p<0.001, Figure 6B), related to a marked inhibition of 
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triglyceride biosynthesis rate compared to the control cells (73%, p<0.001, Figure S4). 
In contrast, upon adding increasing concentrations of HMB or IVA (0-2 mM), no 
significant effects on macrophage cholesterol or triglyceride content were noted (Figure 
6C-F). 
 
3.6. In vitro and in vivo leucine supplementation improves macrophage 
mitochondrial function 
Given the importance of mitochondria in maintaining normal vascular cell function, there 
is growing evidence showing that mitochondrial dysfunction may be correlated with 
atherogenesis and CVD risk (58). To evaluate how macrophage mitochondrial energy 
status is affected by in vitro and in vivo leucine supplementation, macrophage OCR was 
measured with an extracellular flux analyzer (Seahorse Bioscience XF-96, Figure 7A). 
OCR measurements were made in J774A.1 macrophage incubated with leucine (0.2 
mM), and in MPM harvested from the leucine-supplemented mice. In J774A.1 
macrophages, leucine significantly increased mitochondrial basal respiration (by 54%, 
p<0.001), ATP production (by 39%, p<0.001), and maximal respiration (by 25%, p<0.01) 
compared to the control cells (Figure 7B-D). Accordingly, in MPM from the leucine-
supplemented mice, a significant increase in the above three parameters was observed 
(by 28, 31, and 36%, p<0.05, Figure 7E-G). 
 
 
4. DISCUSSION  
Macrophage foam-cell formation is a hallmark feature of early atherogenesis (1, 4). 
Recently, we have studied the anti- or pro-atherogenic effects of all amino acids using a 
macrophage model system, and identified leucine as a potent amino acid able to 
decrease macrophage lipid content in vitro (34). In the current investigation we studied, 
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for the first time, both the in vivo and in vitro roles of leucine in macrophage foam-cell 
formation by supplementing humans, mice and cultured macrophages with leucine. The 
key findings of the present study are: 1) Leucine decreases macrophage lipid 
accumulation as determined ex vivo (humans), in vivo (mice), and in vitro (J774A.1 
macrophages); 2) the metabolic mechanisms by which leucine decreases macrophage 
lipid content include inhibition of cellular cholesterol or triglyceride biosynthesis rate, 
enhancement of cholesterol efflux from macrophages, and attenuation of VLDL uptake; 
3) leucine improves macrophage mitochondrial respiration in vitro and in vivo as shown 
by OCR measurements; 4) unlike other examined leucine metabolites (HMB and IVA), 
KIC, the first leucine metabolite, is able to mimic the lipid-lowering effects of leucine in 
vitro by decreasing macrophage cholesterol and triglyceride contents. 
Leucine is a key amino acid of the BCAA group (accounting for >20% of total 
dietary protein), which has received great attention due to its unique function in 
metabolic regulation, beyond its fundamental role as substrate for protein synthesis (59). 
Leucine has been shown to play an important cardio-metabolic role and to affect CVD 
(10, 16, 22, 30, 31). High dietary leucine intake has been associated with lower 
prevalence of overweight status, obesity, and regulation of glucose homeostasis in mice 
and humans (26). Since adverse effects of high intakes of leucine have not been clearly 
identified, to date, no upper limit or safe intake for this BCAA have been established. In 
our human clinical trial, a leucine dose of 5 g/d was set up based on the average leucine 
daily intake reported in adults (5.3±0.1 g/d) (35). As a result, this daily dose allowed a 
significant increase in leucine serum values at the end of the intervention (21 d), 
compared to baseline values. In contrast, leucine-supplementation did not affect the 
serum lipid profile, glucose concentration or other biochemical parameters that were 
quantified. Further studies involving longer dietary leucine interventions would be useful 
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to determine if changes in serum lipid profile can be observed in healthy subjects and 
also in individuals with increased CVD risk. 
Anti- or pro-atherogenicity of human serum is determined by its ability to 
attenuate or induce lipid accumulation in cultured macrophages (60). In the current 
study, the effects of leucine on human serum atherogenicity were studied for the first 
time. Although leucine supplementation to healthy adults did not alter their serum lipid 
profile and only increased leucine levels, incubation of J774A.1 macrophages with 
serum obtained from participants 21 d after leucine supplementation, significantly 
decreased macrophage cholesterol content, paralleled with a decrease in macrophage 
cholesterol biosynthesis rate. Furthermore, the effect of leucine supplementation on 
serum-mediated cholesterol efflux from macrophages was evaluated. Cholesterol efflux 
is critical for maintaining lipid homeostasis in macrophages, thus its measurement 
constitutes a predictor of atherosclerotic burden (61). By incubating the cells with human 
serum obtained at 21 d of leucine supplementation, a significant increase in the serum-
mediated cholesterol efflux from macrophages was observed. Considering that HDL, the 
key mediator of cholesterol efflux from macrophages (61), was not changed by leucine 
supplementation, these findings highlight an important role for leucine in macrophage 
cholesterol homeostasis, which is independent of the anti-atherogenic properties of HDL. 
However, we cannot discard a possible capacity of leucine to promote structural and 
functional changes in the HDL particles, which could improve their ability to remove 
cholesterol from macrophages (cholesterol efflux), as well as a possible effect of leucine 
on the capacity of the ATP-binding cassette transporters ABCA1/ABCG1 to facilitate 
cholesterol efflux from the macrophages to HDL. The findings of the current clinical-ex 
vivo studies demonstrate novel metabolic mechanisms by which leucine inhibits 
macrophage foam-cell formation and highlight the need to study the anti-atherogenic 
role of leucine in larger cohorts, including CVD patients.   
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In accordance with the human study, leucine supplementation to mice did not 
change their plasma lipid profile, but significantly reduced cholesterol content in 
macrophages isolated from the leucine-supplemented mice, in relation with decreased 
cholesterol biosynthesis rate. Moreover, similar to previous studies where leucine was 
found to decrease hepatic triglyceride accumulation in mice with fatty liver (62), we found 
a significant decrease in hepatic cholesterol and triglycerides in leucine-supplemented 
mice. Since accumulation of lipids in the liver (hepatic steatosis) represents a risk factor 
for the onset and progression of metabolic syndrome and atherosclerosis (63), the lipid-
lowering effects currently observed in livers isolated from leucine-supplemented mice as 
well as in MPM indicate the cardio-metabolic benefits of this amino acid. Our findings are 
consistent with previous studies that demonstrated the cardio-metabolic protection by 
dietary leucine supplementation. For instance, doubling leucine intake in mice fed HFD, 
significantly decreased plasma total cholesterol and LDL levels, improved insulin 
resistance, glucose and cholesterol metabolism, and attenuated weight gain (27).  
Although without statistical significance, we found that aortas isolated from 
leucine-supplemented mice showed a trend toward decreased triglyceride content 
(p=0.052). Recently, leucine was reported to improve the serum lipid profile by 
decreasing VLDL and LDL, and increasing HDL levels, which contributed to attenuate 
the progression of atherosclerotic plaques in apoE-/- mice. Moreover, the hepatic 
cholesterol content in those mice was significantly reduced by leucine supplementation 
(31). Overall, findings from the current investigation, and from the above mentioned 
reports, support a beneficial role of leucine in lipid metabolism and its ability to inhibit 
tissue lipid accumulation, which is a key feature of both fatty liver disease and 
atherosclerosis.   
In accordance with our previous reports on the lipid-lowering effects of leucine in 
macrophages (34), the current investigation revealed that treating J774A.1 macrophages 
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with physiological (up to 0.2 mM, (43)) and supra-physiological (1 and 2 mM) 
concentrations of leucine resulted in a dose-dependent reduction of cellular lipid content. 
Moreover, both AggLDL-induced cholesterol accumulation and VLDL-induced 
triglyceride accumulation were significantly abolished by treating J774A.1 macrophages 
with physiological leucine levels. Interestingly, the in vitro studies demonstrated a 
marked effect of leucine on macrophage triglyceride metabolism. First, leucine 
significantly attenuated the macrophage uptake of VLDL, which are major endogenous 
carriers of triglyceride in the blood circulation, and are implicated in atherosclerosis 
development (64). Uptake of VLDL contributes to triglyceride accumulation and the 
concomitant foam-cell formation (65, 66). In addition to attenuating macrophage VLDL 
uptake, leucine caused a marked decrease in the rate of triglyceride biosynthesis 
associated with down-regulation of DGAT1, a key enzyme in triglyceride biosynthetic 
pathway in macrophages (56). However, unlike the prominent inhibition of triglyceride 
accumulation observed in leucine-treated J774A.1 macrophages, cellular triglyceride 
content remained unaffected after leucine supplementation in vivo. This discrepancy 
could be explained by a different effect exerted on triglyceride metabolism when leucine 
is directly added to the culture medium in vitro, while in vivo, leucine is found in a more 
complex matrix of serum components, which are very likely to influence the utilization of 
leucine by the cells, highlighting the different outcomes regarding lipid metabolism in 
macrophages after direct in vitro leucine exposure versus oral in vivo leucine 
administration. 
Leucine catabolism comprises a first reversible transamination reaction, 
exclusive to the BCAA catabolic pathway, catalyzed by branched-chain 
aminotransferase (BCAT) to generate KIC, a key leucine metabolite (Figure 1). KIC is 
next decarboxylated and converted to its corresponding acyl-CoA derivative (isovaleryl-
CoA) via branched-chain α-keto acid dehydrogenase (BCKDH), to finally generate 
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substrates for the tricarboxylic acids cycle (acetyl-CoA or acetoacetate) (12). KIC can 
follow an alternative pathway via cytosolic oxidation to generate HMB, which might be 
involved in the pathway of cholesterol biosynthesis (57). Similar to leucine and unlike the 
other examined leucine metabolites, we found that treating macrophages with KIC dose-
dependently decreased both cholesterol and triglyceride contents in macrophages. 
Moreover, KIC and leucine markedly inhibited the rate of triglyceride biosynthesis in a 
similar manner. Given the reversibility of the BCAT transamination reaction, both leucine 
and KIC can be interconverted, depending on the metabolic needs of the cell (12). 
According to previous studies, the effects observed after KIC cell-supplementation are 
likely a result of its transamination back to leucine, as it was found in different cell 
models (40, 67). 
Macrophage lipid accumulation also represents one of the mechanisms for 
mitochondrial dysfunction in atherosclerosis (2). Therefore, we assessed the effects of in 
vitro and in vivo leucine supplementation on macrophage mitochondrial energetic status. 
Leucine improved mitochondrial energetic status, represented by a significant increase 
in mitochondrial basal and maximal respiration, as well as mitochondrial ATP production, 
in both leucine-treated J774A.1 macrophages and in MPM from leucine-supplemented 
mice. Mitochondria are critical for cellular function and ATP generation, which is 
essential for metabolic processes, including lipid homeostasis. In macrophages, the 
inhibition of mitochondrial ATP production and function by pharmacologic (oligomycin) or 
genetic (Pgc-1α deletion) means, resulted in a significant reduction in cholesterol efflux 
capacity of the cells (68). Mitochondrial dysfunction has been mechanistically linked to 
the progression of atherosclerosis in the apoE-/- mice model, due in part to defects in 
oxidative phosphorylation (69). On the other hand, augmented mitochondrial respiration 
resulted in reduction of necrotic core areas in atherosclerotic plaques in apoE-/- mice, 
significantly increased cell proliferation and decreased the number of cells undergoing 
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apoptosis. Also, macrophages from these atherosclerotic mice with genetically 
augmented mitochondrial respiration, showed higher OCR after uncoupling with FCCP 
(respiratory reserve capacity), and increased abundance of both mitochondrial 
respiratory complexes I and III, compared with atherosclerotic controls (70). Based on 
these recent findings, the capacity of leucine to increase mitochondrial respiration in 
macrophages in vitro and in vivo reveals a new potential athero-protective feature of this 
amino acid, although the underlying molecular/biochemical mechanisms remain unclear. 
In conclusion then, by studying the role of leucine in macrophage lipid 
metabolism and its mitochondrial energetic status in vivo and in vitro, the current study 
revealed a novel inhibitory effect of leucine in macrophage foam-cell formation, the 
hallmark of early atherogenesis. Thus, leucine ability to modify macrophage lipid 
metabolism with a simultaneous enhancement of mitochondrial respiration, may 
constitute a potential strategy to attenuate atherosclerosis development. Clearly, the 
overall favorable effects exerted by this unique amino acid involve multiple mechanisms, 
and further investigation, including leucine supplementation to humans for extended 
periods of time, and the use of atherosclerotic models, are warranted to fully establish 
the therapeutic approach of leucine supplementation. 
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Table 1. Human anthropometric and biochemical characteristics at baseline visit and 
after leucine supplementation for 21 days. 
 
 
Baseline 
After 
Supplementation 
(21 d) 
p value 
Anthropometric data 
   
Age (years) 27.6±2.0 
  
Height (meters) 1.8±0.0 
  
Body weight (kilograms) 76.2±3.1 76.3±3.06 0.979 
BMI (height/weight2) 24.5±0.8 24.5±0.78 0.977 
Body fat (%) 17.3±1.3 17.9±1.34 0.767 
WHR 0.87±0.0 0.87±0.02 0.874 
Serum Biochemical data 
   
Leucine (µmol/L) 159.4±10.33 217.3±23.62 0.044* 
Glucose (mg/dl) 85.1±3.9 89.6±2.9 0.382 
Triglycerides (mg/dl) 94.1±17.3 88.5±9.7 0.791 
Cholesterol (mg/dl) 173.3±7.8 177.2±8.8 0.748 
LDL-C (mg/dl) 109.0±6.9 111.5±7.7 0.812 
HDL-C (mg/dl) 45.5±3.1 48.0±4.2 0.636 
Total Protein (g/dl) 7.2±0.1 7.3±0.1 0.603 
Albumin (g/dl) 4.6±0.1 4.7±0.1 0.740 
BUN (mg/dl) 13.3±0.8 14.4±1.8 0.563 
Creatinine (mg/dl) 0.8±0.0 0.8±0.0 0.817 
Uric acid (mg/dl) 5.5±0.3 5.3±0.3 0.714 
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AST (U/L) 22.0±2.5 19.4±1.6 0.410 
ALT (U/L) 20.1±2.8 18.1±2.5 0.605 
GGT (U/L) 19.6±3.1 23.2±4.4 0.508 
ALP (U/L) 59.3±4.3 63.3±3.9 0.508 
LDH (U/L) 160.6±9.1 160.0±9.6 0.966 
 
BMI, Body mass index; WHR, waist-to-hips ratio; LDL-C, low-density lipoprotein; HDL-C, 
high-density lipoproteins; BUN, blood urea nitrogen; AST, aspartate aminotransferase; 
ALT, alanine aminotransferase; GGT, γ-glutamyl transpeptidase; ALP, alkaline 
phosphatase; LDH, lactate dehydrogenase. p values for comparison between baseline 
and supplementation outcomes. n= 7 healthy subjects. *p<0.05 vs baseline. Values are 
given as mean±SEM. Independent-Samples T test was used to compare the means 
between baseline and after supplementation values. p<0.05 was considered statistically 
significant.  
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Table 2. Body weight gain, consumption patterns, and serum biochemical parameters in 
C57BL/6 male mice treated with water (control), or with leucine-supplemented water 
(1%, w/v), for 8 weeks.  
 
 
Control Leucine  
(1%, w/v) p value 
BW gain (g)
 a
 5.6±0.4 5.9±0.6 0.706 
Food consumption (mg/BW/d) 100.6±1.8 106.0±2.6 0.100 
Leucine consumption
 
(mg/BW/d) 
b
 
1.4±0.0 3.3±0.1 0.000*** 
Serum Biochemical data 
   
  Leucine (µmol/L) 114.4±6.3 139.2±4.5 0.046* 
Triglycerides (µmol/L) 270.3±6.5 255.8±6.2 0.110 
Cholesterol (µmol/L) 198.1±4.7 187.6±4.5 0.110 
 
a Calculated from the difference in body weight at the start and at the end of the study. 
b Total leucine consumption was calculated from the amount of leucine reported in the 
chow diet plus the quantity of leucine consumed in the drinking water by the mice. 
BW, body weight. n= 8 mice per group. *p<0.05, ***p<0.001 vs Control group. Data are 
given as mean±SEM. Independent-Samples T test was used to compare the means 
between values from control and leucine groups. p<0.05 was considered statistically 
significant.   
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FIGURE LEGENDS 
Figure 1. Leucine catabolic pathway. Gray-dashed squares indicate the main 
enzymes of the pathway. Names in bold letters in the figure correspond to the studied 
compounds and their chemical structure. α-KIC= α-ketoisocaproate; HMB= β-hydroxy-β-
methylbutyrate; α-KG= α-ketoglutarate; IV-CoA= Isovaleryl–Coenzyme A; HMG-CoA= 
Hydroxymethylglutaryl–Coenzyme A; TCA cycle= Tricarboxylic acids cycle. BCAT= 
Branched-chain aminotransferase; BCKDH= Branched-chain ketoacid dehydrogenase. 
 
Figure 2. Atherogenicity of human serum following leucine supplementation in 
J774A.1 macrophages. Serum was harvested from blood collected from each 
participa t at baseline (0 h), after 1 h of leucine consumption, and at the end of the study 
(21 d). J774A.1 macrophages were incubated for 20 h with 2.5% human serum, followed 
by analyses of: (A) Cellular cholesterol mass; (B) Cholesterol biosynthesis rate; and (C) 
Serum-mediated cholesterol efflux from macrophages, evaluated after 3 h of cell 
incubation with 2.5% human serum. Data are shown as % compared to baseline 
(mean±SEM). n= 7 healthy subjects. *p<0.05, **p<0.01 vs. baseline. 
 
Figure 3. Lipid content in MPM and liver from leucine-supplemented mice. Mouse 
peritoneal macrophages (MPM) were harvested and livers were excised from C57BL/6 
male mice treated with water (Control), or with leucine-supplemented water (1%, w/v), 
for 8 weeks as described under the Experimental Procedures section. Lipid content in 
MPM and in livers after lipid extraction and determination of: (A, C) Cholesterol mass; 
(B, D) Triglyceride mass. n= 8 mice per group. *p<0.05, **p<0.01 vs. Control group. 
Data are given as mean±SEM. 
 
Page 40 of 49
John Wiley & Sons
BioFactors
This article is protected by copyright. All rights reserved.
A
ut
ho
r M
an
us
cr
ip
t
41 
 
Figure 4. Effects of leucine on J774A.1 macrophage lipids. Quantifications were 
performed after 20 h of cell incubation with leucine (0.2 mM), followed by cellular lipid 
extraction and determination of: (A) Cholesterol mass; (B) Cholesterol mass after an 
overnight cell loading with aggregated LDL (AggLDL, cholesterol-rich lipoproteins, 50 
µg/mL); (C) Triglycerides mass; and, (D) Triglycerides mass after an overnight cell 
loading with VLDL (triglycerides-rich lipoprotein, 50 µg/mL). n= 6. *p<0.05, **p<0.01, 
***p<0.001 vs Control (0, with no addition).  ###p<0.001 vs cholesterol-rich or 
triglyceride-rich Control, respectively. Data are given as mean±SEM. 
 
Figure 5. Effects of leucine on triglyceride metabolism in cultured J774A.1 
macrophages. Quantifications were performed after 20 h of cell incubation with leucine 
(0.2 mM) followed by (A) Triglyceride biosynthesis rate after 4 h of cell incubation with 
[3H]-oleic acid; (B) qRT-PCR analysis of DGAT1 gene expression; (C) VLDL uptake, 
using FITC-VLDL (24 µg/mL); and, (D) qRT-PCR analysis of CD36 gene expression. n= 
6. *p<0.05, **p<0.01, ***p<0.001 vs Control (with no addition). Data are given as 
mean±SEM. 
 
Figure 6. Effects of leucine metabolites (KIC, HMB, and IVA) in J774A.1 
macrophage lipid content. Quantifications were performed after 20 h of cell incubation 
with increasing concentrations of leucine metabolites (0-2 mM), followed by cellular lipid 
extraction and determination: (A, C, E) Cholesterol mass; and (B, D, F) Triglyceride 
mass. KIC= α-ketoisocaproate, HMB= β-hydroxy-β-methyl-butyric acid, and IVA= 
Isovaleric acid. n= 6. *p<0.05, **p<0.01, ***p<0.001 vs Control (with no addition). Data 
are given as mean±SEM. 
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Figure 7. Mitochondrial energetic status of J774A.1 macrophages and mouse 
peritoneal macrophages (MPM). Quantifications in cultured J774.A1 macrophages 
were performed after 20 h of cell incubation with leucine (0.2 mM). Mouse peritoneal 
macrophages (MPM) were harvested from C57BL/6 male mice treated with water 
(Control), or with leucine-supplemented water (1%, w/v), for up to 8 weeks as described 
under the Experimental Procedures section. All oxygen consumption rate (OCR) 
parameters were calculated after the injection of oligomycin, carbonyl cyanide-4 
(trifluoromethoxy) phenylhydrazone (FCCP), or rotenone + antimycin A. Macrophage 
mitochondrial energetic status determined by: (A) OCR parameters; (B, E) Mitochondrial 
basal respiration; (C, F) Mitochondrial ATP production; and (D, G) Maximal 
mitochondrial respiration. n= 8 mice per group. *p<0.05, **p<0.01, **p<0.001 vs Control 
group. Data are given as mean±SEM. 
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Figure 1. Leucine catabolic pathway. Gray-dashed squares indicate the main enzymes of the pathway. 
Names in bold letters in the figure correspond to the studied compounds and their chemical structure. α-
KIC= α-ketoisocaproate; HMB= β-hydroxy-β-methylbutyrate; α-KG= α-ketoglutarate; IV-CoA= Isovaleryl–
Coenzyme A; HMG-CoA= Hydroxymethylglutaryl–Coenzyme A; TCA cycle= Tricarboxylic acids cycle. BCAT= 
Branched-chain aminotransferase; BCKDH= Branched-chain ketoacid dehydrogenase.  
 
30x40mm (600 x 600 DPI)  
 
 
Page 43 of 49
John Wiley & Sons
BioFactors
This article is protected by copyright. All rights reserved.
A
ut
ho
r M
an
us
cr
ip
t   
 
 
Figure 2. Atherogenicity of human serum following leucine supplementation in J774A.1 macrophages. Serum 
was harvested from blood collected from each participant at baseline (0 h), after 1 h of leucine consumption, 
and at the end of the study (21 d). J774A.1 macrophages were incubated for 20 h with 2.5% human serum, 
followed by analyses of: (A) Cellular cholesterol mass; (B) Cholesterol biosynthesis rate; and (C) Serum-
mediated cholesterol efflux from macrophages, evaluated after 3 h of cell incubation with 2.5% human 
serum. Data are shown as % compared to baseline (mean±SEM). n= 7 healthy subjects. *p<0.05, 
**p<0.01 vs. baseline.  
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Figure 3. Lipid content in MPM and liver from leucine-supplemented mice. Mouse peritoneal macrophages 
(MPM) were harvested and livers were excised from C57BL/6 male mice treated with water (Control), or with 
leucine-supplemented water (1%, w/v), for 8 weeks as described under the Experimental Procedures 
section. Lipid content in MPM and in livers after lipid extraction and determination of: (A, C) Cholesterol 
mass; (B, D) Triglyceride mass. n= 8 mice per group. *p<0.05, **p<0.01 vs. Control group. Data are given 
as mean±SEM.  
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Figure 4. Effects of leucine on J774A.1 macrophage lipids. Quantifications were performed after 20 h of cell 
incubation with leucine (0.2 mM), followed by cellular lipid extraction and determination of: (A) Cholesterol 
mass; (B) Cholesterol mass after an overnight cell loading with aggregated LDL (AggLDL, cholesterol-rich 
lipoproteins, 50 µg/mL); (C) Triglycerides mass; and, (D) Triglycerides mass after an overnight cell loading 
with VLDL (triglycerides-rich lipoprotein, 50 µg/mL). n= 6. *p<0.05, **p<0.01, ***p<0.001 vs Control (0, 
with no addition).  ###p<0.001 vs cholesterol-rich or triglyceride-rich Control, respectively. Data are given 
as mean±SEM.  
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Figure 5. Effects of leucine on triglyceride metabolism in cultured J774A.1 macrophages. Quantifications 
were performed after 20 h of cell incubation with leucine (0.2 mM) followed by (A) Triglyceride biosynthesis 
rate after 4 h of cell incubation with [3H]-oleic acid; (B) qRT-PCR analysis of DGAT1 gene expression; (C) 
VLDL uptake, using FITC-VLDL (24 µg/mL); and, (D) qRT-PCR analysis of CD36 gene expression. n= 6. 
*p<0.05, **p<0.01, ***p<0.001 vs Control (with no addition). Data are given as mean±SEM.  
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Figure 6. Effects of leucine metabolites (KIC, HMB, and IVA) in J774A.1 macrophage lipid content. 
Quantifications were performed after 20 h of cell incubation with increasing concentrations of leucine 
metabolites (0-2 mM), followed by cellular lipid extraction and determination: (A, C, E) Cholesterol mass; 
and (B, D, F) Triglyceride mass. KIC= α-ketoisocaproate, HMB= β-hydroxy-β-methyl-butyric acid, and IVA= 
Isovaleric acid. n= 6. *p<0.05, **p<0.01, ***p<0.001 vs Control (with no addition). Data are given as 
mean±SEM.  
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Figure 7. Mitochondrial energetic status of J774A.1 macrophages and mouse peritoneal macrophages (MPM). 
Quantifications in cultured J774.A1 macrophages were performed after 20 h of cell incubation with leucine 
(0.2 mM). Mouse peritoneal macrophages (MPM) were harvested from C57BL/6 male mice treated with 
water (Control), or with leucine-supplemented water (1%, w/v), for up to 8 weeks as described under the 
Experimental Procedures section. All oxygen consumption rate (OCR) parameters were calculated after the 
injection of oligomycin, carbonyl cyanide-4 (trifluoromethoxy) phenylhydrazone (FCCP), or rotenone + 
antimycin A. Macrophage mitochondrial energetic status determined by: (A) OCR parameters; (B, E) 
Mitochondrial basal respiration; (C, F) Mitochondrial ATP production; and (D, G) Maximal mitochondrial 
respiration. n= 8 mice per group. *p<0.05, **p<0.01, **p<0.001 vs Control group. Data are given as 
mean±SEM.  
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